secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2025-04-09T23:59:59+00:00
Accession:  0001193125-25-076358
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Pharmaceuticals: Health Canada accepts AGAMREE NDS with Priority Review for DMD
--------------------------------------------------------------------------------

- Health Canada accepted New Drug Submission for AGAMREE (corticosteroid) for Duchenne muscular dystrophy.
- Submission granted Priority Review; potential marketing authorization before end of 2025.
- If approved, AGAMREE would be first and only DMD treatment indicated in Canada.
- AGAMREE already FDA-approved (Oct 2023) and commercially available in the U.S. since March 2024.
- Sub-licensee Kye Pharmaceuticals markets FIRDAPSE in Canada for LEMS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312525076358/0001193125-25-076358-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312525076358/d941124d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-076358

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer